567 completed, 105 recruiting, 52 active not recruiting, 45 unknown. 875 Phase 1, 176 Phase 2.
Follow Nutrition Disorders: new trials by email Literature Review of Nutrition Disorders trials Research Report on Nutrition Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity Survodutide formulation A, Survodutide formulation D1 - Healthy, Obesity | Phase 1 | Not yet recruiting | Boehringer Ingelheim | 80 | 2026-12-03 | 2026-11-16 |
| A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity. IBIO-610, Placebo - Obesity & Overweight | Phase 1 | Not yet recruiting | iBio, Inc. | 32 | 2026-12-01 | 2026-10-22 |
| Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Vanderbilt University Medical Center | 30 | 2026-12-01 | 2026-11-12 |
| Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity Liver-expressed antimicrobial peptide 2, Placebo - Obesity & Overweight | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Gentofte, Copenhagen | 18 | 2026-11-30 | 2026-10-27 |
| A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants UBT48128, Placebo - Overweight , Obesity | Phase 1 | Not yet recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 60 | 2026-11-29 | 2026-11-06 |
| Study of IPG1094 Tablets in Chinese Healthy Adults and Obese Adults IPG1094 Tablet and matching Placebo - Healthy Volunteers; Obesity | Phase 1 | Not yet recruiting | Nanjing Immunophage Biotech Co., Ltd | 72 | 2026-11-25 | 2026-11-13 |
| A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity. QLS2406-1 injection, Placebo - Overweight and Obesity, MASH - Metabolic Dysfunction-Associated Steatohepatitis | Phase 1 | Not yet recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 124 | 2026-11-20 | 2026-11-16 |
| A Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Participants Zovaglutide - Overweight, Obesity | Phase 1 | Not yet recruiting | Beijing QL Biopharmaceutical Co.,Ltd | 24 | 2026-11-13 | 2026-11-04 |
| Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) Maridebart cafraglutide - Obesity, Overweight | Phase 1 | Recruiting | Amgen | 180 | 2026-11-13 | 2026-11-02 |
| Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses Maridebart cafraglutide - Obesity, Overweight | Phase 1 | Not yet recruiting | Amgen | 356 | 2026-11-09 | 2026-11-06 |
| A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection - Healthy Participants | Phase 1 | Not yet recruiting | AstraZeneca | 60 | 2026-11-09 | 2026-11-02 |
| A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet Dose 1, Dose 2 - Food Effect in Healthy Volunteers, Weight Management | Phase 1 | Not yet recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 72 | 2026-11-03 | 2026-11-13 |
| Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal Function DA-302168S - Obesity & Overweight | Phase 1 | Recruiting | Chendu DIAO Pharmaceutical Group CO., LTD. | 32 | 2026-11-02 | 2026-11-16 |
| A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy LY4247147, Placebo - Obesity, Overweight | Phase 1 | Not yet recruiting | Eli Lilly and Company | 108 | 2026-11-01 | 2026-11-04 |
| Brain Dopamine Dynamics in Obesity Milkshake, NeuroEXPLORER, [11C]raclopride - Obesity | Phase 1 | Not yet recruiting | Yale University | 100 | 2026-11-01 | 2026-11-04 |
| A Study to Investigate the Effect of Injection Site and Ethnicity on KAI-4729 Pharmacokinetics in Non-Asian and Asian Participants Living With Obesity or Overweight KAI-4729 - Overweight or Obesity | Phase 1 | Not yet recruiting | Kailera | 60 | 2026-11-01 | 2026-11-09 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity Placebo, PF-08656795 - Overweight and/or Obesity | Phase 1 | Not yet recruiting | Pfizer | 150 | 2026-10-30 | 2026-10-15 |
| Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function DA-302168S - Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chendu DIAO Pharmaceutical Group CO., LTD. | 32 | 2026-10-22 | 2026-10-15 |
Showing 20 of 875. Sign in to see all of them.
Obesity (733) · Overweight (336) · Diabetes Mellitus, Type 2 (89) · Insulin Resistance (39) · Weight Loss (38) · Diabetes Mellitus (36) · Vitamin D Deficiency (35) · Metabolic Syndrome (23) · Non-alcoholic Fatty Liver Disease (23) · Hypertension (20) · Motor Activity (19) · Body Weight (16) · Obesity, Morbid (16) · Metabolic Diseases (15)
Nutritional and Metabolic Diseases (874) · Pathological Conditions, Signs and Symptoms (808) · Overnutrition (798) · Signs and Symptoms (794) · Body Weight (777) · Overweight (465) · Metabolic Diseases (184) · Glucose Metabolism Disorders (162) · Endocrine System Diseases (132) · Diabetes Mellitus (89) · Malnutrition (63) · Deficiency Diseases (60) · Avitaminosis (59) · Hyperinsulinism (49)
semaglutide (35) · Cholecalciferol (19) · Acetaminophen (18) · Tirzepatide (17) · Sodium Chloride (16) · Metformin (15) · Liraglutide (12) · Rosuvastatin Calcium (12) · BI 456906 (11) · Vitamin D (11) · cagrilintide (10) · Exercise (9) · Warfarin (9) · Atorvastatin (8) · Digoxin (8)
Novo Nordisk A/S (86) · Eli Lilly and Company (40) · Pfizer (31) · AstraZeneca (24) · Amgen (17) · Boehringer Ingelheim (17) · Mayo Clinic (14) · Vanderbilt University Medical Center (14) · GlaxoSmithKline (10) · Columbia University (9) · University of Pittsburgh (9) · BrightGene Bio-Medical Technology Co., Ltd. (8) · Shanghai Minwei Biotechnology Co., Ltd (8) · Stanford University (8) · Yale University (8)
United States (450) · China (109) · Germany (50) · Australia (37) · Canada (36) · United Kingdom (33) · France (12) · Japan (12) · Singapore (12) · South Korea (12) · Denmark (11) · Netherlands (10) · Brazil (9) · Egypt (8) · Spain (8)
Joshua R Cook, MD, PhD (7) · Jack A Yanovski, M.D. (5) · John M Jakicic, Ph.D. (4)
PMID 12150647, PMID 25919461, PMID 36524539, PMID 36690550, PMID 40576086, PMID 41747885, PMID 10560680, PMID 11245554, PMID 11433905, PMID 12679447, PMID 12841897, PMID 15598683, PMID 15671108, PMID 15681386, PMID 16818482, PMID 16864756, PMID 17065354, PMID 17116758, PMID 17194194, PMID 18310192, PMID 18316660, PMID 18385391, PMID 18400730, PMID 18491071, PMID 18635428, PMID 18825363, PMID 18957534, PMID 19142567, PMID 19244376, PMID 19433800, PMID 19461456, PMID 19475464, PMID 19487105, PMID 19595348, PMID 19635145, PMID 19698154, PMID 19776051, PMID 19796996, PMID 19816674, PMID 19934630, PMID 20194883, PMID 20214807, PMID 20455886, PMID 20457158, PMID 20528109, PMID 20551965, PMID 20725058, PMID 20810979, PMID 20847735, PMID 20881066
2025 (13), 2023 (7), 2019 (5), 2014 (4), 2018 (3), K23DK140614 (3), P30DK063608 (3), 2009 (2), K12DK133995 (2), K23HL103976 (2), K24DK059492 (2), R01DK091748 (2), 1OT2CA297680-01 (1), 2008 (1), 2017 (1)